Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
FierceBiotech5h
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...
Ventyx stock climbs 8% on $27M Sanofi investment
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...
ENDPOINTS NEWS6h
Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.
Business Insider12h
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties in ...